Patents by Inventor Yabin Lu
Yabin Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11827940Abstract: Disclosed herein is a method which includes extracting genomic deoxyribonucleic acid (DNA) at locations at or near cancer hotspots from a subject, modifying Tier-1 5hmC on the DNA to a modified 5hmC, detecting and identifying the presence or absence of the modified 5hmC, quantifying the detected and identified modified 5hmC; and providing a report comprising a score, wherein the score is indicative of the presence of cancer.Type: GrantFiled: October 7, 2022Date of Patent: November 28, 2023Inventors: Yabin Lu, Michael Jinyang Lu
-
Publication number: 20230227915Abstract: Disclosed herein is a method which includes extracting genomic deoxyribonucleic acid (DNA) at locations at or near cancer hotspots from a subject, modifying Tier-1 5hmC on the DNA to a modified 5hmC, detecting and identifying the presence or absence of the modified 5hmC, quantifying the detected and identified modified 5hmC; and providing a report comprising a score, wherein the score is indicative of the presence of cancer.Type: ApplicationFiled: October 7, 2022Publication date: July 20, 2023Inventors: Yabin Lu, Michael Jinyang Lu
-
Patent number: 11365405Abstract: The invention is directed to methods and kits which utilize an immobilized solid support to extract the nucleic acids present in the human plasma sample Immobilized solid support further comprises: a) a pre-treated solid support material b) M-Aminophenylboronic acid (APBA), and c) levoglucosenone. The components and methods for activating solid support and extraction of nucleic acids used in the invention provide for high extraction efficiency and the resultant product is a highly purified plasma which is almost completely free of nucleic acids.Type: GrantFiled: March 19, 2020Date of Patent: June 21, 2022Assignee: ANCHOR MOLECULAR INC.Inventor: Yabin Lu
-
Publication number: 20210355480Abstract: A method to simultaneously create multiple SNV, INDEL or fusion sequences harbored in a single cell line is provided. The method uses the CRISPR/Cas9 gene editing system to generate large sequence knock-in cell lines in an AAVS1 locus, or other safe harbor sites. Also provided is a method that allows specifically engineered quantitative marker sequences to accurately reflect copy numbers of inserted SNV, INDEL and fusion sequences. These methods allow accurate measurement of ratio or allele frequencies of genetic variants in a cell.Type: ApplicationFiled: March 27, 2021Publication date: November 18, 2021Inventors: Yabin Lu, Gang Li
-
Patent number: 10921315Abstract: Methods of diagnosing celiac disease in a subject are provided. In some embodiments, the method comprises contacting a sample of bodily fluid from the subject with an antigen comprising a recombinant or synthetic deamidated gliadin protein, wherein the deamidated gliadin protein comprises a hexamer of peptides each having the sequence of SEQ ID NO:1; and detecting an antibody from the sample that specifically binds to the antigen, thereby diagnosing celiac disease in the subject.Type: GrantFiled: June 8, 2017Date of Patent: February 16, 2021Assignee: Bio-Rad Laboratories, Inc.Inventors: Roger Walker, Yabin Lu, Urvee Desai, Daming Shan
-
Publication number: 20200299673Abstract: The invention is directed to methods and kits which utilize an immobilized solid support to extract the nucleic acids present in the human plasma sample Immobilized solid support further comprises: a) a pre-treated solid support material b) M-Aminophenylboronic acid (APBA), and c) levoglucosenone. The components and methods for activating solid support and extraction of nucleic acids used in the invention provide for high extraction efficiency and the resultant product is a highly purified plasma which is almost completely free of nucleic acids.Type: ApplicationFiled: March 19, 2020Publication date: September 24, 2020Inventor: Yabin Lu
-
Publication number: 20170307633Abstract: Methods of diagnosing celiac disease in a subject are provided. In some embodiments, the method comprises contacting a sample of bodily fluid from the subject with an antigen comprising a recombinant or synthetic deamidated gliadin protein, wherein the deamidated gliadin protein comprises a hexamer of peptides each having the sequence of SEQ ID NO:1; and detecting an antibody from the sample that specifically binds to the antigen, thereby diagnosing celiac disease in the subject.Type: ApplicationFiled: June 8, 2017Publication date: October 26, 2017Inventors: Roger Walker, Yabin Lu, Urvee Desai, Daming Shan
-
Patent number: 9702885Abstract: The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a hexamer of a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing the gliadin fusion protein on the solid support. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase.Type: GrantFiled: December 3, 2012Date of Patent: July 11, 2017Assignee: Bio-Rad Laboratories, Inc.Inventors: Roger Walker, Yabin Lu, Urvee Desai, Daming Shan
-
Publication number: 20140278536Abstract: A computer implemented method and system provides a mobile application development platform (MADP) for dynamically creating a healthcare provider specific customizable composite mobile application (CCMA) and monitoring healthcare elements of a healthcare recipient using the CCMA. The MADP is accessible by a healthcare provider device and a healthcare recipient device via a network. The MADP stores multiple template objects, for example, sub-applications that perform tasks for monitoring the healthcare elements in an application management database (AMD). The MADP acquires a selection of one or more template objects and one or more dynamic content objects defined by a healthcare provider and dynamically creates the CCMA by integrating the selected template objects and dynamic content objects. The MADP stores the CCMA in the AMD. The CCMA facilitates communication between the healthcare provider device and the healthcare recipient device for monitoring the healthcare elements of the healthcare recipient.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Inventors: Dongxiao Zhang, Di Shan, Chen Peng, Yabin Lu
-
Patent number: 8620590Abstract: Methods, systems, and apparatus for accurately determining a proportion (ratio) of two analytes is provided, as well as provide a concentration of a first analyte from a determined concentration of a second analyte and from a proportion of the analytes to each other. In one aspect, a surface model (called a “dose surface” herein) relating the concentrations of the two analytes to the proportion can be used to obtain accurate values for one of the variables (e.g. a concentration or the proportion) when the other two variables have previously been obtained. The dose surface can be a three-dimensional surface and be non-linear. The dose surface model can include multiple regression functions. For example, measured responses can be individually converted to concentrations using two dose-response curves, and the concentrations can be input to a dose surface function to obtain the proportion.Type: GrantFiled: September 30, 2010Date of Patent: December 31, 2013Assignee: Bio-Rad Laboratories, Inc.Inventors: Yabin Lu, Roger Walker
-
Patent number: 8260556Abstract: The ratio of analytes is determined directly from the responses of the analytes using a conversion method. Individual analyte responses are obtained by using a selected measuring technique, and these individual responses are used as the independent variables in a conversion method. The dependent variable of conversion method is the desired analyte ratio. The resulting conversion method is then used to directly calculate the desired ratio of analytes as a function of the measured responses. No intermediate conversions, such as using a calibration curve to convert individual measured analyte responses to concentration values, are needed to obtain the desired ratio.Type: GrantFiled: August 21, 2008Date of Patent: September 4, 2012Assignee: Bio-Rad Laboratories, Inc.Inventors: Robert Likuski, Roger Walker, Yabin Lu
-
Publication number: 20120084010Abstract: Methods, systems, and apparatus for accurately determining a proportion (ratio) of two analytes is provided, as well as provide a concentration of a first analyte from a determined concentration of a second analyte and from a proportion of the analytes to each other. In one aspect, a surface model (called a “dose surface” herein) relating the concentrations of the two analytes to the proportion can be used to obtain accurate values for one of the variables (e.g. a concentration or the proportion) when the other two variables have previously been obtained. The dose surface can be a three-dimensional surface and be non-linear. The dose surface model can include multiple regression functions. For example, measured responses can be individually converted to concentrations using two dose-response curves, and the concentrations can be input to a dose surface function to obtain the proportion.Type: ApplicationFiled: September 30, 2010Publication date: April 5, 2012Applicant: Bio-Rad Laboratories, Inc.Inventors: Yabin Lu, Roger Walker
-
Publication number: 20100049444Abstract: The ratio of analytes is determined directly from the responses of the analytes using a conversion method. Individual analyte responses are obtained by using a selected measuring technique, and these individual responses are used as the independent variables in a conversion method. The dependent variable of conversion method is the desired analyte ratio. The resulting conversion method is then used to directly calculate the desired ratio of analytes as a function of the measured responses. No intermediate conversions, such as using a calibration curve to convert individual measured analyte responses to concentration values, are needed to obtain the desired ratio.Type: ApplicationFiled: August 21, 2008Publication date: February 25, 2010Applicant: BIO-RED LABORATORIES, INC.Inventors: Robert Likuski, Roger Walker, Yabin Lu